secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001651308-24-000032
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene appoints Titus Ball as principal accounting officer; amends director compensation
--------------------------------------------------------------------------------

- Titus Ball named principal accounting officer effective March 19, 2024; succeeded Julia Wang, who remains CFO.
- Ball joined in Aug 2023 as VP, Chief Accounting Officer; prior roles at Carlisle, KPMG, PwC.
- Independent director cash retainers increased: Nominating Committee chair to $20,000 (+$2K), members to $10,000 (+$1K).
- No changes to equity award structure ($400K initial and annual grant, 50/50 options/RSUs).
- Amended policy effective April 1, 2024; full text filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000032/0001651308-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000032/bgne-20240319.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer